IMRX — Immuneering Corp
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1790340 ·
Last close
$4.19
Market Cap
$271.08M
52W High
$6.89
52W Low
$3.86
ADV30
1,833,393
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -15,334,539 | -13,460,895 | 214,809,790 | 47,321,566 | 8,291,619 |
| Dec 2025 | 0 | — | -13,751,943 | -11,580,010 | 231,985,010 | 128,645,025 | 13,501,042 |
| Sep 2025 | 0 | — | -15,380,300 | -14,964,875 | 241,056,266 | 227,563,077 | 13,079,834 |
| Jun 2025 | 0 | — | -14,757,477 | -14,433,881 | 40,056,468 | 26,355,498 | 11,120,431 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-49,697,401
Investing CF
$-151,800,077
Financing CF
$212,953,348
CapEx
$-213,211
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.17
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-293,780,979
Inventory
—
Receivables
—
ST Investments
$109,372,057
EBIT TTM
$-59,224,259
Pretax Income TTM
$-54,437,567
Interest Exp TTM
—
Analysts
6
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -59,375,728 | -56,024,898 | 231,985,010 | 13,501,042 | — | -45,344,595 |
| Dec 2024 | 0 | -64,071,655 | -61,036,608 | 52,714,413 | 11,328,187 | — | -54,999,571 |
| Dec 2023 | 0 | -58,413,285 | -53,471,622 | 102,584,538 | 12,008,355 | — | -48,968,634 |
| Dec 2022 | 316,952 | -51,745,339 | -50,513,568 | 122,367,283 | 12,517,028 | — | -44,101,265 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$1,751,499
NetIncome TTM
$-53,234,615
OpCashFlow TTM
$0
Assets (Latest)
$52,714,413
Forward EPS
$-1.34
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ZNTL | Zentalis Pharmaceuticals, Inc. | $266.95M | $3.75 | — |
| ELDN | Eledon Pharmaceuticals, Inc. | $275.56M | $3.57 | — |
| RNAC | Cartesian Therapeutics, Inc. | $279.42M | $9.51 | — |
| ELTX | Elicio Therapeutics, Inc. | $283.43M | $14.85 | — |
| NVCT | Nuvectis Pharma, Inc. | $284.09M | $10.71 | — |
News headlines (Yahoo Finance, 1h cache)
Immuneering Appoints Andrew Gengos as Chief Financial Officer
2026-06-15 11:30 · Yahoo
IMRX Begins Dosing in Phase III Pancreatic Cancer Study, Stock Up
2026-06-12 13:48 · Yahoo
Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer
2026-06-11 11:30 · Yahoo
IMRX Stock On Track For Worst Day In Nearly 5 Months — What’s Driving The Selloff?
2026-06-01 19:58 · Yahoo
Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO
2026-06-01 11:30 · Yahoo
Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy
2026-05-21 21:00 · Yahoo
Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates
2026-05-15 11:35 · Yahoo
We're Hopeful That Immuneering (NASDAQ:IMRX) Will Use Its Cash Wisely
2026-05-06 14:53 · Yahoo
Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting
2026-04-21 20:05 · Yahoo
Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond
2026-04-20 13:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.